MARKET

LPCN

LPCN

Lipocine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.430
+0.030
+2.14%
After Hours: 1.410 -0.02 -1.40% 19:16 03/05 EST
OPEN
1.380
PREV CLOSE
1.400
HIGH
1.430
LOW
1.240
VOLUME
2.66M
TURNOVER
--
52 WEEK HIGH
2.420
52 WEEK LOW
0.3010
MARKET CAP
117.42M
P/E (TTM)
-3.2382
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Lipocine, Athersys, Norwegian Cruise Line, Newage Inc, or GameStop?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPCN, ATHX, NCLH, NBEV, and GME.
PR Newswire - PRF · 3d ago
Lipocine shares up after LPCN 1144 preclinical study results
Lipocine (LPCN) shares rise nearly 6% premarket after announcing the publication of preclinical results supporting the therapeutic potential of LPCN 1144 in the treatment of and non-alcoholic steatohepatitis ("NASH") and hepatic fibrosis.The results were
Seekingalpha · 3d ago
SKT, BLRX, LPCN and ECOR among premarket gainers
Severn Bancorp (SVBI) +82% on merger agreement with Shore Bancshares.Tanger Factory Outlet Centers (SKT) +21%.Allied Esports Entertainment Inc. (AESE) +19%.Bellicum Pharmaceuticals (BLCM) +14%. on first reported use of CaspaCIDe® Safety Switch.Soligenix
Seekingalpha · 3d ago
Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis
SALT LAKE CITY, March 4, 2021 /PRNewswire via COMTEX/ -- SALT LAKE CITY, March 4, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage...
PR Newswire - PRF · 3d ago
8-K: Lipocine Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference
, - /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the ENDO 2021 Conference, to take ...
PR Newswire - PRF · 4d ago
Lipocine to Present at Two Upcoming Investor Conferences
SALT LAKE CITY, Feb. 26, 2021 /PRNewswire via COMTEX/ -- SALT LAKE CITY, Feb. 26, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage...
PR Newswire - PRF · 02/26 13:00
4 Top Penny Stocks For Your Watch List, Are They A Buy Now?
Feb 24, 2021 (Penny Stocks via COMTEX) -- So far, in 2021, it seems as though this is the year of penny stocks. Many companies have seen their share prices...
Penny Stocks · 02/24 21:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LPCN. Analyze the recent business situations of Lipocine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LPCN stock price target is 5.33 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 8.75M
% Owned: 10.65%
Shares Outstanding: 82.11M
TypeInstitutionsShares
Increased
10
1.08M
New
16
475.96K
Decreased
3
252.86K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mahesh Patel
Chief Financial Officer/Executive Vice President
Morgan Brown
Vice President
Nachiappan Chidambaram
Lead Director/Independent Director
Stephen Hill
Director
John Higuchi
Independent Director
Jeffrey Fink
Independent Director
Richard Ono
No Data
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products. The Company's primary development programs are based on oral delivery solutions for bioavailable drugs. The Company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. Its lead product candidate, TLANDO, is an oral testosterone replacement therapy. Its additional pipeline includes, an oral androgen therapy for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, LPCN 1144; a once daily oral testosterone replacement therapy, TLANDO XR (LPCN 1111); an androgen therapy for the treatment of NASH cirrhosis, LPCN 1148, and an oral therapy for the prevention of preterm birth, LPCN 1107.

Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.